Hilma Biocare CJC-1295 DAC

32.00

EU Warehouse 1

Company: Hilma Biocare
Active Half-life (Hours): 6 to 8h
Group: Peptide hormone
Subgroup: Injection powder
Dosage: 2 mg (2000 mcg)
Application (Men): 1000 mcg in 3 to 4 days
Product pack:  1 vial
Content (active): CJC-1295 DAC
Retains water: Yes
Aromatization: No

Hilma Biocare CJC-1295 DAC

The first appearance of CJC-1295 DAC was in 2005, presented by the Canadian biotechnology company ConjuChem. Unlike the peptides of the GHRP group, CJC-1295 DAC releases growth hormone evenly in small amounts without sharp jumps in GH in the blood and has similar effects to growth hormone. After a single injection of CJC-1295 DAC, the concentration of the hormone in the blood increases by 2-10 times within six days. Used by the athletes for various purposes of performance enhancement.

Effects of Hilma Biocare CJC-1295 DAC:

By using Hilma Biocare CJC-1295 DAC athletes can increase muscle gains and performance and get rid of unwanted fat. Additionally, it raises collagen synthesis for tendons and ligament reinforcement and overall body wellbeing.

Side-Effects:

CJC-1295 DAC is a peptide and does not result in adverse reactions associated with anabolic steroids. The most common adverse reactions attributed to the CJC-1295 DAC are excessive water retention and weakness.

Stacking:

Hilma Biocare CJC-1295 DAC shows excellent results and can be safely applied in combination with other peptides, any AAS like Stanozolol and HGH.

 

**CJC-1295 DAC: Enhancing Growth Hormone Secretion for Extended Duration**

CJC-1295 DAC, an innovative peptide in the realm of growth hormone modulation, has garnered attention for its ability to stimulate prolonged growth hormone release. This synthetic peptide belongs to the growth hormone-releasing hormone (GHRH) analogs and offers unique advantages in terms of sustained growth hormone elevation and potential therapeutic applications.

**1. Extended Half-Life:**

The distinctive feature of CJC-1295 DAC lies in its extended half-life compared to other peptides. The addition of Drug Affinity Complex (DAC) technology enhances its stability and prolongs its activity, leading to a more sustained release of growth hormone.

**2. Growth Hormone Stimulation:**

CJC-1295 DAC operates by mimicking the action of endogenous GHRH. It binds to and activates the growth hormone-releasing hormone receptor, prompting the secretion of growth hormone from the pituitary gland. The extended duration of action allows for a more gradual and prolonged release of growth hormone.

**3. Potential Therapeutic Applications:**

In a medical context, CJC-1295 DAC has shown promise in addressing growth hormone deficiencies and related conditions. Its ability to provide a sustained elevation in growth hormone levels makes it a candidate for therapeutic use in individuals with insufficient growth hormone secretion.

**4. Performance Enhancement:**

Athletes and individuals in the fitness community may turn to CJC-1295 DAC for its potential benefits in performance enhancement. The prolonged release of growth hormone can contribute to muscle growth, recovery, and overall physical performance.

**5. Dosage and Administration:**

Dosages of this Peptide should be approached with precision, considering individual factors and specific goals. Subcutaneous injections are a common method of administration. Adherence to recommended dosages and guidelines is essential to optimize benefits and minimize the risk of potential side effects.

**6. Combination with GHRP:**

This Peptide is often used in conjunction with Growth Hormone Release Peptides (GHRPs) to amplify the overall impact on growth hormone release. This combination, known as a peptide blend or “peptide stack,” aims to enhance the pulsatile release of growth hormone synergistically.

**7. Professional Guidance:**

Given the complexity of hormonal modulation, seeking professional guidance from healthcare providers or specialists in endocrinology is crucial when incorporating this Peptide into a regimen. Regular monitoring of hormone levels ensures a balanced approach and minimizes the risk of potential side effects.

In summary, this Peptide stands out as a peptide with the potential to revolutionize growth hormone modulation. Its extended duration of action and potential therapeutic applications, coupled with performance-enhancing benefits, make it a subject of interest in the fields of medicine and fitness. Responsible use, individualized protocols, and professional oversight are fundamental in harnessing the positive effects of this Peptide while minimizing potential risks.

Reviews

There are no reviews yet.

Be the first to review “Hilma Biocare CJC-1295 DAC”

Your email address will not be published. Required fields are marked *

English